Login / Signup

Outpatient Intravenous Remdesivir to Prevent Progression to Severe COVID-19: An Observational Study from a Greek Hospital.

Nikolaos KintrilisIosif Galinos
Published in: Recent advances in anti-infective drug discovery (2023)
Among non-hospitalized patients with at least one risk factor for progression to severe COVID-19, a 3-day course of intravenous remdesivir yielded favourable results.
Keyphrases
  • coronavirus disease
  • sars cov
  • high dose
  • early onset
  • healthcare
  • respiratory syndrome coronavirus
  • drug induced
  • emergency department
  • acute care
  • adverse drug